Biomanufacturing is undergoing transformative innovation to enhance flexibility and scalability. Ori Biotech pioneers modular, Lego-like platforms enabling adaptable production workflows for gene-edited therapies, integrating best-in-class technologies like MaxCyte’s electroporation and Fresenius Kabi’s fill-finish. ProBio inaugurated a 128,000-square-foot GMP plasmid and viral vector manufacturing facility in New Jersey, providing end-to-end cell and gene therapy support. Moreover, research combining cell-free protein synthesis with vesicle delivery systems promises to improve therapeutic protein production and delivery. These advances aim to overcome longstanding challenges in manufacturing complex biologics.